Qiagen (QGEN) Earns Daily Coverage Optimism Rating of 0.10

News coverage about Qiagen (NASDAQ:QGEN) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Qiagen earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.5636945659665 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

NASDAQ:QGEN traded up $0.24 during midday trading on Friday, reaching $32.82. The company had a trading volume of 669,018 shares, compared to its average volume of 1,049,764. Qiagen has a 12-month low of $27.83 and a 12-month high of $36.34. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69.

Qiagen (NASDAQ:QGEN) last released its earnings results on Wednesday, January 31st. The company reported $0.43 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.01. The firm had revenue of $396.86 million during the quarter, compared to analyst estimates of $394.48 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. sell-side analysts forecast that Qiagen will post 1.34 earnings per share for the current year.

Qiagen declared that its board has initiated a share buyback plan on Wednesday, January 31st that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

QGEN has been the subject of several research analyst reports. DZ Bank restated a “neutral” rating on shares of Qiagen in a research report on Tuesday, December 19th. BidaskClub upgraded Qiagen from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Cowen restated a “hold” rating and set a $34.00 price target on shares of Qiagen in a research report on Thursday, December 21st. Evercore ISI initiated coverage on Qiagen in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $35.00 price target for the company. Finally, Commerzbank restated a “buy” rating on shares of Qiagen in a research report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company. Qiagen currently has an average rating of “Hold” and an average target price of $35.11.

TRADEMARK VIOLATION WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/04/16/qiagen-qgen-earns-daily-coverage-optimism-rating-of-0-10.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Insider Buying and Selling by Quarter for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply